Precision Ophthalmology Sterile Repackaged Bevacizumab Manufacturing
In the high-stakes field of retinal health, sterility and precision are non-negotiable. Zeptide Pharma has established itself as a premier 503B and 506E leading sterile manufacturer, specializing in the supply of repackaged Bevacizumab for intravitreal injection.
By combining rigorous regulatory compliance with advanced manufacturing technology, we provide healthcare professional supplies and bulk insurance solutions that bridge the gap between clinical excellence and cost-effectiveness.
World-Class Manufacturing: ISO-4 and ISO-5 Clean Rooms
At Zeptide Pharma, our commitment to safety is backed by our infrastructure. Our GMP-approved site features state-of-the-art ISO-4 and ISO-5 clean rooms, ensuring an ultra-sterile environment for the handling of sensitive biologics.
Unlike standard compounding pharmacies, our facility operates as a 503B outsourcing facility, adhering to cGMP (current Good Manufacturing Practice) standards. Every batch of our sterile repackaged Bevacizumab is supported by FDA DMF (Drug Master File) documentation, providing insurance payers and medical directors with total transparency regarding the quality and origin of the components used. This documentation ensures that every syringe meets the highest federal standards for identity, strength, and purity.
Optimized Delivery: Prefilled Syringes for Intravitreal Use
One of the primary challenges in ophthalmology is the accurate delivery of micro-doses. Zeptide Pharma eliminates the risks associated with multi-dose vials by providing repackaged Bevacizumab in prefilled syringes.
Our manufacturing process focuses on the recommended doses per prefilled syringe—typically 1.25mg/0.05mL—specifically designed for the treatment of:
- Wet Age-Related Macular Degeneration (wAMD)
- Diabetic Macular Edema (DME)
- Retinal Vein Occlusion (RVO)
By utilizing a prefilled syringe format, we significantly reduce the potential for needle-stick contamination, diminish medication waste, and eliminate "drawing up" errors in the clinic. This ensures that healthcare professionals can focus on patient outcomes with a "ready-to-use" sterile injectable that is consistently accurate.
A Strategic Partner for Insurance and Health Systems
The rising cost of ophthalmic biologics has placed a significant burden on the insurance sector. Zeptide Pharma serves as a vital resource for cost-mitigation without compromising patient care. Under Section 506E of the FD&C Act, which identifies drugs that may be compounded or repackaged by 503B facilities, we provide a stable, high-quality alternative to high-cost brand-name equivalents.
Our bulk insurance supply model offers:
- Massive Cost Savings: Empowering payers to provide access to essential retinal therapies at a fraction of the cost of specialty brands.
- Supply Chain Stability: Reducing the impact of commercial drug shortages through our robust manufacturing capacity.
- Extended Beyond-Use Dating (BUD): Our cGMP-validated testing allows for longer shelf life compared to traditional compounding, easing inventory management for large health systems.
Secure Your Sterile Supply Chain with Zeptide Pharma
As a 503B and 506E leading sterile manufacturer, Zeptide Pharma is dedicated to the highest levels of ophthalmic safety. From our FDA DMF documented processes to our ultra-clean ISO-4 and ISO-5 environments, we provide the reliability that modern medicine demands.
Experience the difference that cGMP-compliant manufacturing brings to your practice or patient network. Partner with Zeptide Pharma for your repackaged Bevacizumab needs and ensure your facility is equipped with the gold standard in sterile injectables.
Contact the Zeptide Pharma procurement team today to discuss bulk supply contracts and clinical formulations.
